They say lightning rarely strikes twice but Kezar Life Sciences has suffered its second clinical blow in as many months.

Despite this success, investors were unimpressed with the topline data, with Syndax’s stock dropping by 25.6%, from $21.78 ...

Longboard has commenced the Phase III DEEp OCEAN Study of bexicaserin for treating seizures linked to DEEs in two years and ...

Medical advances and better knowledge of health have contributed to increased life expectancy and a growing elderly ...

At two upcoming events on rare disease clinical trials and data management, experts will dissect the latest trends and ...

Lyophilization plays a crucial role in successful biologic molecule development, but what is lyophilization – and how can it ...